Radcliffe Capital Management, L.P. Pacira Bio Sciences, Inc. Transaction History
Radcliffe Capital Management, L.P.
- $6.73 Million
- Q3 2025
A detailed history of Radcliffe Capital Management, L.P. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Radcliffe Capital Management, L.P. holds 47,589 shares of PCRX stock, worth $1.13 Million. This represents 18.23% of its overall portfolio holdings.
Number of Shares
47,589Holding current value
$1.13 Million% of portfolio
18.23%Shares
1 transactions
Others Institutions Holding PCRX
# of Institutions
262Shares Held
48.9MCall Options Held
118KPut Options Held
63.7K-
Black Rock Inc. New York, NY8.01MShares$190 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.2MShares$124 Million0.0% of portfolio
-
Doma Perpetual Capital Management LLC Miami, FL2.7MShares$64.2 Million23.38% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$51.4 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.14MShares$50.8 Million0.08% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.09B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...